

Appl. No. : 10/063,523  
Filed : May 2, 2002

### AMENDMENTS TO THE CLAIMS

1. (Cancelled)
2. (Cancelled)
3. (Cancelled)
4. (Previously presented) An isolated polypeptide having at least 95% amino acid sequence identity to:
  - (a) the amino acid sequence of the polypeptide of SEQ ID NO:22;
  - (b) the amino acid sequence of the polypeptide of SEQ ID NO:22 lacking its associated signal peptide; or
  - (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209963, wherein the polypeptide is more highly expressed in normal stomach than in stomach tumor, or wherein the polypeptide is encoded by a polynucleotide that is more highly expressed in normal stomach than in stomach tumor.
5. (Previously presented) The isolated polypeptide of Claim 4 having at least 99% amino acid sequence identity to:
  - (a) the amino acid sequence of the polypeptide of SEQ ID NO:22;
  - (b) the amino acid sequence of the polypeptide of SEQ ID NO:22 lacking its associated signal peptide; or
  - (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209963, wherein the polypeptide is more highly expressed in normal stomach than in stomach tumor, or wherein the polypeptide is encoded by a polynucleotide that is more highly expressed in normal stomach than in stomach tumor.
6. (Previously Presented) An isolated polypeptide comprising:
  - (a) the amino acid sequence of the polypeptide of SEQ ID NO:22;
  - (b) the amino acid sequence of the polypeptide of SEQ ID NO:22 lacking its associated signal peptide; or
  - (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209923.

Appl. No. : 10/063,523  
Filed : May 2, 2002

7. **(Previously Presented)** The isolated polypeptide of Claim 6 comprising the amino acid sequence of the polypeptide of SEQ ID NO:22.

8. **(Previously Presented)** The isolated polypeptide of Claim 6 comprising the amino acid sequence of the polypeptide of SEQ ID NO:22, lacking its associated signal peptide.

9-10. **(Cancelled)**

11. **(Previously presented)** The isolated polypeptide of Claim 6 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209923.

12. **(Previously presented)** A chimeric polypeptide comprising a polypeptide according to Claim 4 fused to a heterologous polypeptide.

13. **(Currently Amended)** The chimeric polypeptide of Claim 12, wherein the heterologous polypeptide is ~~an epitope~~ a tag polypeptide or an Fc region of an immunoglobulin.

14. **(Previously presented)** An isolated polypeptide having at least 95% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:22;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:22 lacking its associated signal peptide; or
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209923;

wherein said isolated polypeptide or a fragment thereof can be used to generate an antibody which can be used to specifically detect the polypeptide of SEQ ID NO: 22 in stomach tissue samples.

15. **(Previously presented)** The isolated polypeptide of Claim 14 having at least 99% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:22;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:22 lacking its associated signal peptide; or
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209923;

**Appl. No.** : **10/063,523**  
**Filed** : **May 2, 2002**

wherein said isolated polypeptide or a fragment thereof can be used to generate an antibody which can be used to specifically detect the polypeptide of SEQ ID NO: 22 in stomach tissue samples.

16. **(Previously presented)** A chimeric polypeptide comprising a polypeptide according to Claim 14 fused to a heterologous polypeptide.

17. **(Previously presented)** The chimeric polypeptide of Claim 16, wherein said heterologous polypeptide is a tag polypeptide or an Fc region of an immunoglobulin.